Allogeneic Hematopoietic Stem Cell Transplantation for Adults with Sickle Cell Disease

Overview

Journal J Clin Med

Specialty General Medicine

Date 2019 Oct 5

PMID 31581479

Citations 4

Authors

Santosh L Saraf

Damiano Rondelli

Affiliations

Soon will be listed here.

Abstract

Sickle cell disease (SCD) is an inherited red blood cell disorder that leads to substantial morbidity and early mortality. Acute and chronic SCD-related complications increase with older age, and therapies are urgently needed to treat adults. Allogeneic hematopoietic stem cell transplantation (HSCT) is a curative therapy, but has been used less frequently in adults compared to children. This is, in part, due to (1) greater chronic organ damage, limiting tolerability to myeloablative conditioning regimens, (2) a higher rate of HSCT-related complications in adults versus children with SCD, and (3) limited coverage by public and private health insurance. Newer approaches using nonmyeloablative and reduced-intensity conditioning HSCT regimens have demonstrated better safety and tolerability, with high rates of stable engraftment in SCD adults. This review will focus on the impacts of HSCT, using more contemporary approaches to SCD-related complications in adults.

Citing Articles

Hematopoietic Stem Cell Transplantation in Sickle Cell Disease: A Multidimentional Review.

Rostami T, Rad S, Rostami M, Mirhosseini S, Alemi H, Khavandgar N Cell Transplant. 2024; 33:9636897241246351.

PMID: 38680015 PMC: 11057353. DOI: 10.1177/09636897241246351.

Low dose post-transplant cyclophosphamide and sirolimus induce mixed chimerism with CTLA4-Ig or lymphocyte depletion in an MHC-mismatched murine allotransplantation model.

Kabore M, McElrath C, Ali M, Almengo K, Gangaplara A, Fisher C Bone Marrow Transplant. 2024; 59(5):615-624.

PMID: 38347187 PMC: 11073977. DOI: 10.1038/s41409-024-02237-y.

Inhibition of the Aquaporin-1 Cation Conductance by Selected Furan Compounds Reduces Red Blood Cell Sickling.

Chow P, Cox C, Pei J, Anabaraonye N, Nourmohammadi S, Henderson S Front Pharmacol. 2022; 12:794791.

PMID: 35111062 PMC: 8801817. DOI: 10.3389/fphar.2021.794791.

Hematopoietic cell transplantation for sickle cell disease: updates and future directions.

Krishnamurti L Hematology Am Soc Hematol Educ Program. 2021; 2021(1):181-189.

PMID: 34889368 PMC: 8791142. DOI: 10.1182/hematology.2021000251.

References

Gladwin M, Sachdev V, Jison M, Shizukuda Y, Plehn J, Minter K . Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. N Engl J Med. 2004; 350(9):886-95. DOI: 10.1056/NEJMoa035477. View

Desai A, Lei Z, Bahroos N, Maienschein-Cline M, Saraf S, Zhang X . Association of circulating transcriptomic profiles with mortality in sickle cell disease. Blood. 2017; 129(22):3009-3016. PMC: 5454338. DOI: 10.1182/blood-2016-11-752279. View

Fitzhugh C, Hsieh M, Taylor T, Coles W, Roskom K, Wilson D . Cyclophosphamide improves engraftment in patients with SCD and severe organ damage who undergo haploidentical PBSCT. Blood Adv. 2018; 1(11):652-661. PMC: 5727815. DOI: 10.1182/bloodadvances.2016002972. View

Van Besien K, Bartholomew A, Stock W, Peace D, Devine S, Sher D . Fludarabine-based conditioning for allogeneic transplantation in adults with sickle cell disease. Bone Marrow Transplant. 2000; 26(4):445-9. DOI: 10.1038/sj.bmt.1702518. View

Walters M, Patience M, Leisenring W, Eckman J, Buchanan G, Rogers Z . Barriers to bone marrow transplantation for sickle cell anemia. Biol Blood Marrow Transplant. 1996; 2(2):100-4. View

Saraf S, Oh A, Patel P, Jalundhwala Y, Sweiss K, Koshy M . Nonmyeloablative Stem Cell Transplantation with Alemtuzumab/Low-Dose Irradiation to Cure and Improve the Quality of Life of Adults with Sickle Cell Disease. Biol Blood Marrow Transplant. 2015; 22(3):441-8. DOI: 10.1016/j.bbmt.2015.08.036. View

McClish D, Penberthy L, Bovbjerg V, Roberts J, Aisiku I, Levenson J . Health related quality of life in sickle cell patients: the PiSCES project. Health Qual Life Outcomes. 2005; 3:50. PMC: 1253526. DOI: 10.1186/1477-7525-3-50. View

Steinberg M, Barton F, Castro O, Pegelow C, Ballas S, Kutlar A . Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment. JAMA. 2003; 289(13):1645-51. DOI: 10.1001/jama.289.13.1645. View

Saraf S, Oh A, Patel P, Sweiss K, Koshy M, Campbell-Lee S . Haploidentical Peripheral Blood Stem Cell Transplantation Demonstrates Stable Engraftment in Adults with Sickle Cell Disease. Biol Blood Marrow Transplant. 2018; 24(8):1759-1765. PMC: 6108914. DOI: 10.1016/j.bbmt.2018.03.031. View

10.

Machado R, Hildesheim M, Mendelsohn L, Remaley A, Kato G, Gladwin M . NT-pro brain natriuretic peptide levels and the risk of death in the cooperative study of sickle cell disease. Br J Haematol. 2011; 154(4):512-20. PMC: 3206726. DOI: 10.1111/j.1365-2141.2011.08777.x. View

11.

Angelucci E, Matthes-Martin S, Baronciani D, Bernaudin F, Bonanomi S, Cappellini M . Hematopoietic stem cell transplantation in thalassemia major and sickle cell disease: indications and management recommendations from an international expert panel. Haematologica. 2014; 99(5):811-20. PMC: 4008115. DOI: 10.3324/haematol.2013.099747. View

12.

Pawlowska A, Cheng J, Karras N, Sun W, Wang L, Bell A . HLA Haploidentical Stem Cell Transplant with Pretransplant Immunosuppression for Patients with Sickle Cell Disease. Biol Blood Marrow Transplant. 2017; 24(1):185-189. DOI: 10.1016/j.bbmt.2017.08.039. View

13.

Luznik L, Engstrom L, Iannone R, Fuchs E . Posttransplantation cyclophosphamide facilitates engraftment of major histocompatibility complex-identical allogeneic marrow in mice conditioned with low-dose total body irradiation. Biol Blood Marrow Transplant. 2002; 8(3):131-8. DOI: 10.1053/bbmt.2002.v8.pm11939602. View

14.

Kuentz M, Robin M, Dhedin N, Hicheri Y, Peffault de Latour R, Rohrlich P . Is there still a place for myeloablative regimen to transplant young adults with sickle cell disease?. Blood. 2011; 118(16):4491-2. DOI: 10.1182/blood-2011-07-367490. View

15.

Gluckman E . Allogeneic transplantation strategies including haploidentical transplantation in sickle cell disease. Hematology Am Soc Hematol Educ Program. 2013; 2013:370-6. DOI: 10.1182/asheducation-2013.1.370. View

16.

Ballas S . The cost of health care for patients with sickle cell disease. Am J Hematol. 2009; 84(6):320-2. DOI: 10.1002/ajh.21443. View

17.

Mentzer W, Heller S, Pearle P, Hackney E, Vichinsky E . Availability of related donors for bone marrow transplantation in sickle cell anemia. Am J Pediatr Hematol Oncol. 1994; 16(1):27-9. View

18.

Bhatia M, Kolva E, Cimini L, Jin Z, Satwani P, Savone M . Health-related quality of life after allogeneic hematopoietic stem cell transplantation for sickle cell disease. Biol Blood Marrow Transplant. 2015; 21(4):666-72. PMC: 5580933. DOI: 10.1016/j.bbmt.2014.12.007. View

19.

Piel F, Steinberg M, Rees D . Sickle Cell Disease. N Engl J Med. 2017; 376(16):1561-1573. DOI: 10.1056/NEJMra1510865. View

20.

Ozdogu H, Boga C, Yeral M, Kozanoglu I, Gereklioglu C, Aytan P . Allogenic peripheral stem cell transplantation from HLA-matched related donors for adult sickle cell disease: remarkable outcomes from a single-center trial. Bone Marrow Transplant. 2018; 53(7):880-890. DOI: 10.1038/s41409-018-0111-y. View